Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge

Moderna (MRNA) shares fell 7% to $135.22 after a 392% year-to-date increase, as traders took profits. Despite the decline, the stock has seen significant gains, reaching a record high of $176.66 last week. There were no new negative catalysts reported, and profit-taking appears orderly, with high trading volume noted. The company’s recent phase 3 melanoma trial remains a strong point for investors, as the mRNA therapy's positive data continues to support the bullish sentiment. This decline presents an opportunity for investors to reassess positions in Moderna amidst ongoing developments in its key cancer therapies.